Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Neuwirt

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Leukemia & Lymphoma|October 26, 2020
Azacitidine is removed effectively by hemodialysisA G E Beer, E Laille, H Neuwirt, et al.
Aktuelle Urologie|July 28, 2009
[Androgens stimulate the expression of SOCS-3 and inhibits their effect on proliferation and secretion]H Neuwirt, M Puhr, I T Cavarretta, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|February 11, 2018
A rare case of Epstein-Barr virus-associated hepatosplenic smooth muscle tumors after kidney transplantationC Pircher, S Schneeberger, C Boesmueller, et al.
The Journal of Urology|June 19, 2007
Fetal distribution of 5alpha-reductase 1 and 5alpha-reductase 2, and their input on human prostate developmentA Lunacek, C Schwentner, J Oswald, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 15, 2011
Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic reviewM E Hellemons, J Kerschbaum, S J L Bakker, et al.
Oncogene|October 31, 2006
The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1I T Cavarretta, H Neuwirt, G Untergasser, et al.
Oncogene|August 11, 2015
PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancerM Puhr, J Hoefer, A Eigentler, et al.
Journal of Nephrology|December 31, 2020
Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injuryN Steiner, A Abdel Hamid, A Kronbichler, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Leukemia & Lymphoma|October 26, 2020
Azacitidine is removed effectively by hemodialysisA G E Beer, E Laille, H Neuwirt, et al.
Aktuelle Urologie|July 28, 2009
[Androgens stimulate the expression of SOCS-3 and inhibits their effect on proliferation and secretion]H Neuwirt, M Puhr, I T Cavarretta, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|February 11, 2018
A rare case of Epstein-Barr virus-associated hepatosplenic smooth muscle tumors after kidney transplantationC Pircher, S Schneeberger, C Boesmueller, et al.
The Journal of Urology|June 19, 2007
Fetal distribution of 5alpha-reductase 1 and 5alpha-reductase 2, and their input on human prostate developmentA Lunacek, C Schwentner, J Oswald, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 15, 2011
Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic reviewM E Hellemons, J Kerschbaum, S J L Bakker, et al.
Oncogene|October 31, 2006
The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1I T Cavarretta, H Neuwirt, G Untergasser, et al.
Oncogene|August 11, 2015
PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancerM Puhr, J Hoefer, A Eigentler, et al.
Journal of Nephrology|December 31, 2020
Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injuryN Steiner, A Abdel Hamid, A Kronbichler, et al.
Pageof 1